

KALP YETMEZLİĞİ OLAN HASTALARDA FARMASÖTİK BAKIM

Neda TANER

© Copyright 2021

Bu kitabın, basım, yayın ve satış hakları Akademisyen Kitabevi A.Ş.'ne aittir. Anılan kuruluşun izni alınmadan kitabın tümü ya da bölümleri mekanik, elektronik, fotokopi, manyetik kağıt ve/veya başka yöntemlerle çoğaltılamaz, basılamaz, dağıtılamaz. Tablo, şekil ve grafikler izin alınmadan, ticari amaçlı kullanılamaz. Bu kitap T.C. Kültür Bakanlığı bandrolü ile satılmaktadır.

*Bu Çalışma danışmanlığını Prof. Dr. Barkın BERK'in yaptığı Neda TANER'e ait "Kalp Yetmezliği Olan Hastalarda Farmasötik Bakım" isimli tezinden üretilmiştir.

ISBN

978-625-7679-56-5

Kitap Adı

Kalp Yetmezliği Olan Hastalarda Farmasötik Bakım

Yazar

Neda TANER

Yayın Koordinatörü

Yasin Dilmen

Sayfa ve Kapak Tasarımı

Akademisyen Dizgi Ünitesi

Yayıncı Sertifika No

47518

Baskı ve Cilt

Vadi Matbaacılık

Bisac Code

MED072000

DOI

10.37609/akya.827

GENEL DAĞITIM

Akademisyen Kitabevi A.Ş.

Halk Sokak 5 / A

Yenişehir / Ankara

Tel: 0312 431 16 33

siparis@akademisyen.com

www.akademisyen.com

TEŞEKKÜR

En başta tez boyunca yapıcı görüşleri ve her türlü bilgi ve tecrübesiden yararlandığım tez danışmanım, Klinik Eczacılık Ana Bilim Dalı Başkanı, **Prof. Dr. Barkın BERK’e**

Hastanenin tüm imkânlarını sunan, tez çalışmam sırasında değerli deneyim ve bilgilerinden faydalandığım ‘Medipol Mega Hastanesi Kardiyoloji Anabilim Dalı **Öğretim Üyesi Doç. Dr. Ekrem GÜLER’e**

Eğitimim ve tezimin tüm aşamalarında bilgisini, yardımını ve manevi desteğini esirgemeyen değerli hocam **Prof. Dr. Mesut SANCAR, Prof. Dr. Recep Serdar ALPAN, Dr. Öğretim Üyesi Nilay AKSOY’a**

Eğitim hayatım süresince her türlü desteği sunan, adım adım daha büyük başarılarla ulaşmam için önüme her türlü imkân ve fırsatı sağlayan İstanbul Medipol Üniversitesi Eczacılık Fakültesi Dekanı **Prof. Dr. Gülden Zehra OMURTAG’a**

Her daim yanımda olan, sonsuz teşvik ve desteklerini esirgemeyen İstanbul Medipol Üniversitesi kurucu rektörü **Prof. Dr. Sabahattin AYDIN’a**

Son olarak bugünlere gelmemde her türlü fedakarlığı yapan, yegâne motivasyonum sevgili aileme, bizi biz yapan değerli arkadaşlarıma teşekkürü bir borç bilirim.

Ecz. Neda TANER



İÇİNDEKİLER

1. BÖLÜM

GİRİŞ VE AMAÇ

2. BÖLÜM

2. GENEL BİLGİLER

2.1. Kalp Yetmezliği.....	5
2.2. Epidemiyoloji.....	5
2.3. Patofizyoloji	6
2.4. Kalp yetmezliğinin tipleri.....	6
2.5. Risk Faktörleri	9
2.6. Kalp Yetmezliğinde Semptomlar ve Bulgular.....	10
2.7. Tanı.....	11
2.7.1. Framingham kriterleri:	12
2.7.1.1. Major kriterler	12
2.7.1.2. Minör kriterler	13
2.7.3. Akut başlangıçlı olmayan (kronik) kalp yetmezliği tanı algoritması.....	13
2.7.4. Kardiyak görüntüleme ve diğer tanısal testler	14
2.7.4.1. Akciğer grafisi	14
2.7.4.2. Transtorasik ekokardiyografi (TTE)	14
2.7.4.3. Transözefageal ekokardiyografi (TEE).....	14
2.7.4.4. Stres ekokardiyografi.....	14
2.7.4.6. SPECT/PET	14
2.7.4.7. Koroner anjiyografi	15
2.7.4.8. Kardiyak bilgisayarlı tomografi.....	15
2.7.4.9. Diğer tanısal testler	15
2.8.1. Non-farmakolojik tedavi	15

2.8.2. Farmakolojik tedavi	17
2.8.2.1. ADE (Anjiotensin Dönüştürücü Enzim) inhibitörleri ...	19
2.8.2.1.1. Asemptomatik sol ventriküler disfonksiyonda ADE inhibitörleri.....	20
2.8.2.1.2. Semptomatik kalp yetmezliğinde ADE inhibitörleri.	20
2.8.2.2. Diüretikler	22
2.8.2.2.1. Potasyum tutucu diüretikler	23
2.8.2.2.2. Aldosteron reseptör antagonistleri – spironolakton..	24
2.8.2.3. Anjiotensin II reseptör antagonistleri	25
2.8.2.4. Kardiyak glikozidler	25
2.8.2.5. Hidralazin-izosorbid dinitrat	26
2.8.2.6. Alfa adrenerjik blokaj yapan ilaçlar.....	27
2.8.2.7. Kalsiyum antagonistleri	27
2.8.2.8. Pozitif inotropik ajanlar	27
2.8.2.8.1. Dopaminerjik ajanlar.....	28
2.8.2.10. Beta Bloker ajanlar.....	29
2.8.2.10.1. -Bloker ajanlar arasındaki farklar	30
2.10. Klinik Eczacının Rolü.....	35
2.12. İlaçla İlgili Problemlerin Neden ve Sonuçları	37
2.12.1. İlaçla ilişkili problemlerin kaynakları.....	40
2.12.1.1. İlaç/doz seçimi	40
2.12.2.2. İlaç uygulama süreci.....	40
2.12.2.3. Bilgi eksikliği nedeniyle meydana gelen İİP'ler.....	40
2.12.2.4. Hastanın kendisinden kaynaklanan ya da psikolojik durumuna bağlı gelişebilecek İİP'ler	41
2.12.2.5. Eczane (Lojistik):	41
2.12.3. İlaçla ilgili problemlerin risk faktörlerinin sınıflandırılması.	41
2.12.3.1. Özel ilaçlarla tedaviler.....	41
2.12.3.2. Terapötik ajanlar	42
2.12.3.3. İlaçla ilgili problemlere öncelik tanımak.....	42

2.12.3.4. Hastaneye yatış.....	43
2.12.4. İİP'lerin Kategorileri.....	44
2.12.5. Amerikan sağlık sistemi eczacıları birliği (ASHP) sınıflandırması	46
2.13. İlaçla İlgili Problemlerin Giderilmesinde Eczacının Rolü.....	47
2.14. PCNE	49

3. BÖLÜM

MATERYAL VE METOT

3.1. Bireyler.....	51
3.2. Araçlar	52
3.3. Değerlendirme.....	52
3.3.1. PCNE V8.0	55
3.3.1.2. Problemin sebepleri.....	55
3.3.1.3. Planlanmış müdahaleler	57
3.3.1.4. Müdahalenin kabul durumu	57
3.3.1.5. İlaçla ilgili problemlerin durumu	57

4. BÖLÜM

BULGULAR

4.1. Hastaların Demografik Özellikleri	60
4.2. Farmasötik Bakım Anketi Değerlendirilmesi	63
4.3. Morisky Tedaviye Uyunc Ölçeği Değerlendirilmesi.....	71
4.4. SF-36 Yaşam Kalitesi Anketi Değerlendirilmesi	77
4.5. PCNE Değerlendirilmesi.....	90

5. BÖLÜM

TARTIŞMA VE SONUÇ

KAYNAKLAR	107
------------------------	------------



KISALTMALAR LİSTESİ

ADEİ:	A jiyotensin Dönüştürücü Enzim İnhibitörleri
AF:	Atriyal Fibrilasyon
AİK:	Akılcı İlaç Kullanımı
AİR:	Advers İlaç Reaksiyonu
ANZ:	Avusturalya-Yeni Zelanda Karvedilol Çalışması
ARB:	Anjiyotensin Reseptör Blokörleri
ASHP:	Amerikan Hastane Eczacıları Birliği
AV: A	triyoventriküler
BNP:	Beyin Natriüretik Peptit cAMP: Siklik Adenozin Mono
Fosfat CCU:	Koroner Bakım Ünitesi
CMR:	Kardiyak Manyetik Rezonans
CoQ10:	Koenzim Q 10
EF:	Ejeksiyon Fraksiyonu
EKG:	Elektrokardiyograf EKO: Ekokardiyografi
GFR:	Glomerüler Filtrasyon Hızı
HfmrEF:	Orta Derecede Sistolik Disfonksiyona Eşlik Eden Diyastolik Disfonksiyon
HFpEF:	Ejeksiyon Fraksiyonu Korunmuş Kalp Yetmezliği
HFrEF:	İndirgenmiş Ejeksiyon Fraksiyonu Hgb: Hemoglobin
IVC:	İnferior Vena Kava
İİP:	İlaçla İlişkili Problemler K: Potasyum

KAH:	Koroner Arter Hastalıđı
KCFT:	Karaciđer Fonksiyon Testleri KKY: Kronik Kalp Yetmezliđi
KOAH:	Kronik Obstrüktif Akciđer Hastalıđı
KPR:	KardiyoPulmoner Resüsitasyon
KY:	Kalp yetmezliđi
LV:	Sol ventrikül
LVEF:	Sol Ventrikül Ejeksiyon Fraksiyonu
MR:	Manyetik Rezonans
Na:	Sodyum
NYHA:	New York Kalp Cemiyeti
NP:	Natriüretik Peptit
NSAİ:	Nonsteroidal Antiinflamatuvar İlaçlar
OTC:	Tezgâh Üstü İlaç
PCNE:	Pharmaceutical Care Network Europe
PET:	Pozitron Emisyon Tomografisi
SPECT:	Tek Foton Emisyon Bilgisayarlı Tomografi
TEE:	Transözefageal Ekokardiyografi
TSH:	Tiroksin stimüle edici hormon
TTE:	Transtorasik Ekokardiyografi
Wbc:	Beyaz Kan Hücreleri
WHO:	Dünya Sağlık Örgütü
YBÜ:	Yođun Bakım Ünitesi

KAYNAKLAR

1. Mcneely EB. Treatment Considerations and the Role of the Clinical Pharmacist Throughout Transitions of Care for Patients With Acute Heart Failure. 30(4);441–50, 2017.
2. Alemzadeh-Ansari MM, Naderi N, MJ A-R. Chronic pain in chronic heart failure: A review article. J Tehran Univ Hear Cent.12(2);49–56, 2017.
3. Figueroa MS, Faarc JIP. Congestive Heart Failure : Diagnosis , Pathophysiology , Therapy , and Implications for Respiratory Care. 403–12, 2006.
4. Azad N, Lemay G. Management of chronic heart failure in the older population. 329–37, 2014.
5. Jaarsma T, Stromberg A, Martensson J, Dracup K. Development and testing of the European Heart Failure Self-Care Behaviour Scale. 5;363–70, 2003.
6. Wiffen P, Mitchell M, Snelling M. Oxford Handbook of Clinical Pharmacy. third edit. OUP Oxford, 2017.
7. Kunkel M, Krämer I. The impact of a clinical pharmacist on the duration of drug related problems. Int J Clin Pharm. 34(1);219, 2012.
8. Reddenna L, K SN. Drug Therapy Problems : A Review of Literature. PharmaTutor. 2(2);111–6, 2014.
9. Adriano LS, Martins BCC, Lima LF, Cavalcante RM de A, De Oliveira FRP, Magalhães VP, et al. Pharmaceutical interventions and their clinical outcomes in an inpatient post-transplant unit. Rev Bras Farm Hosp Serv Saúde São Paulo. 8(1);15–21, 2017.
10. O'Loughlin J, Masson P, Déry V, Fagnan D. The role of community pharmacists in health education and disease prevention: A survey of their interests and needs in relation to cardiovascular disease. Prev Med (Baltim). 28(3);324–31, 1999.
11. Van den Bemt P, Egberts A. Drug-related problems: definitions and classification. EJHP Pract. 13(1);62–4, 2007
12. Riet EES Van, Hoes AW, Wagenaar KP, Limburg A, Landman MAJ, Rutten FH. Epidemiology of heart failure : the prevalence of heart failure and ventricular dysfunction in older adults over time . A systematic review. 242–52, 2016.
13. Task A, Members F, Ponikowski P, Poland C, Voors AA, Germany SDA, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure The Task Force for the diagnosis

- and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution . 1–85, 2016.
14. Butler J, Fonarow GC, Zile MR, Lam CS, Roessig L, Schelbert EB, et al. Developing Therapies for Heart Failure With Preserved Ejection Fraction Current State and Future Directions. 2(2), 2014
 15. Bermejo RA, Babarro EG, López Canoa JN, Román AV, Otero IG, Ayude MO, et al. Heart failure with recovered ejection fraction: Clinical characteristics, determinants and prognosis. 25(3);353–62, 2018.
 16. Tariq S, Aronow WS. Use of Inotropic Agents in Treatment of Systolic Heart Failure. 29060–8, 2015.
 17. Lipkin DP, Canepa-anson R, Stephens MR, Poole-wilson PA. Factors determining symptoms in heart failure : comparison of fast and slow exercise tests. 1986.
 18. France AC, McMurray JJ V, Poland PP, Uk PAP, Veldhuisen DJ Van, Atar D, et al. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology . 2388–442, 2008.
 19. Crespo-Leiro MG, Metra M, Lund LH, Milicic D, Costanzo MR, Filippatos G, et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. 20(11);1505–35, 2018.
 20. Karataş P. Kalp yetersizliđi hastalarında tedavi profilinin belirlenmesi ve statinlerin inflamasyon ve yaşam kalitesi üzerine etkilerinin incelenmesi. 2010.
 21. Gandhi TK, Weingard SN, Borus J, Seger AC, Peterson J, Burdick E, et al. Adverse drug events in ambulatory care. N Engl J Med. 348(16);1556–64, 2003.
 22. Ashaye A, Gaziano J, Djousse L. Red meat consumption and risk of heart failure in male physicians. 2011.
 23. Danelich IM, Reed BN, Sueta CA. Stage A : Can Heart Failure Be Prevented ? 4–9, 2015
 24. Stein GY, Kremer A, Shochat T, Bental T, Korenfeld R, Abramson E, et al. The Diversity of Heart Failure in a Hospitalized Population : The Role of Age. J Card Fail. 18(8);645–53, 2012.
 25. Lazzarini V, Mentz RJ, Fiuzat M, Metra M, Connor CMO. Heart failure in elderly patients : distinctive features and unresolved issues. 717–23, 2013.

26. Gheorghiade M, Zannad F, Sopko G, Klein L, Piña IL, Konstam MA, et al. Acute Heart Failure Syndromes Definition. 3958–68, 2015.
27. Mosterd A, Bloemen JA, Valk MJ, Velzen E Van, Wielders JP, Zuithoff NP, et al. Clinical evaluation of geriatric outpatients with suspected heart failure : value of symptoms, signs, and additional tests. 518–27, 2011.
28. Filippatos G, Parissis JT. Heart failure diagnosis and prognosis in the elderly : the proof of the pudding is in the eating. 467–71, 2011.
29. Nwosu C, Mezue K, Bhagatwala K, Ezema N. A Practical Comprehensive Approach to Management of Acute Decompensated Heart Failure. *Curr Cardiol Rev.* 12;311–7, 2016
30. Martindale JL, Wakai A, Collins SP, Levy PD, Diercks D, Hiestand BC, et al. Diagnosing Acute Heart Failure in the Emergency Department: A Systematic Review and Meta-analysis. *Acad Emerg Med.* 23(3);223–42, 2016.
31. Ravera A, Carubelli V, Sciatti E, Bonadei I, Gorga E, Cani D, et al. Nutrition and Cardiovascular Disease : Finding the Perfect Recipe for Cardiovascular Health. 2016.
32. Abshire M, Xu J, Baptiste D, Johana R, Xu J, Cummings A, et al. Nutritional interventions in heart failure: A systematic review of the literature. *J Card Fail.* 21(12);989–99, 2016
33. Payne-emerson H, Lennie TA. Nutritional Considerations in Heart Failure. 43:117–32, 2008.
34. Sciatti E, Lombardi C, Ravera A, Vizzardi E, Bonadei I, Carubelli V, et al. Nutritional Deficiency in Patients with Heart Failure. 2016.
35. Iwane M, Ph D. Influenza Vaccination and Reduction in Hospitalizations for Cardiac Disease and Stroke among the Elderly. 1322–32, 2003
36. Chavey WE, Hogikyan R V, Harrison RVAN. Heart Failure Due to Reduced Ejection Fraction : Medical Management. 2017.
37. Johnson W, Omland T, Hall C, Lucas C, Myking OL, Collins C, et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. *J Am Coll Cardiol.* 39(10):1623–9, 2002.
38. Whittlesea C, Walker R CW. Clinical Pharmacy and therapeutics. Fifth Edit. Elsevierh Health MEA. 2012.

39. Schwinghammer TL, Wells BG., Joseph T. DiPiro CVD. Pharmacotherapy Handbook. Edition, N. McGraw-Hill Education. 2017.
40. Braunwald E. Congestive heart failure: A half century perspective. *Eur Heart J.* 22(10);825–36, 2001.
41. Kajstura J, Cigola E, Malhotra A, Li P, Cheng W, Meggs LG, et al. Angiotensin II induces apoptosis o.f adult ventricular myocytes in vitro. *J Mol Cell Cardiol.* 29(3);859–70, 1997.
42. New THE, Journal E, Medicine OF. a Clinical Trial of the Angiotensin- Converting – Enzyme Inhibitor Trandolapril in Patients With Left Ventricular Dysfunction After. 1670–6, 1995.
43. Flather MD, Yusuf S, Køber L, Pfeffer M, Hall A, Murray G, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. *Lancet.* 355(9215);1575–81, 2000.
44. Ljungman S, Kjekshus J, Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril. *70(4);479–87,* 1992
45. Chiaranda G, Bernardi E, Codecà L, Conconi F, Myers J, Terranova F, et al. Treadmill walking speed and survival prediction in men with cardiovascular disease. *3(10),* 2013.
46. Channer KS, Mclean KA, Richardson M. Combination diuretic treatment in severe heart failure : a randomised controlled trial.146–50, 1994.
47. Suliburska J, Skrypnik K, Szulińska M, Kupsz J, Markuszewski L, Bogdański P. Diuretics, ca-antagonists, and angiotensin-converting enzyme inhibitors affect zinc status in hypertensive patients on monotherapy: A randomized trial. *Nutrients.*10(9);1–15, 2018.
48. MacFadyen RJ, Barr CS SA. Aldosterone blockade reduces vascular collagen turnover,improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. *Cardio-vasc Res.*35;30-34, 1997.
49. Burnier M, Brunner HR. New drug classes Angiotensin II receptor antagonists. 355, 2000.
50. Nieuwlaet R, Eurlings LW, Cleland JG, Cobbe SM, Vardas PE, Capucci A, et al. Atrial Fibrillation and Heart Failure in Cardiology Practice: Reciprocal Impact and Combined Management From the Perspective of Atrial Fibrillation. Results of the Euro Heart Survey on Atrial Fibrillation. *J Am Coll Cardiol.* 53(18);1690–8, 2009.

51. D.Isemaman.M.D M. The New England Journal of Medicine Downloaded from nejm.org at UNIV & LANDESBIBLIOTHEK DUSSELDORF on December 24, 2013.
52. U ST, Witte K, Clark AL, Cleland JGF. Clinical trials update : OP-TIME-CHF , PRAISE-2. 209-12, 2000.
53. Hampton JR, Veldhuisen D, Kleber FX, Cowley AJ, Ardia A, Block P, et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. *Lancet*. 349(9057);971-7, 1997.
54. Cleland JG, Cowburn PJ, Falk RH. Should all patients with atrial fibrillation receive warfarin? Evidence from randomized clinical trials. *Eur Hear J*. 17(5);674-81, 1996.
55. Fowler MB, Laser JA, Hopkins GL, Minobe W, Bristow MR. Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. *Circulation*. 74(6);1290-302, 1986.
56. Cabezas CL, Salvador CF, Quadrada DC, Bartés AA, Boré MY, Perea NM, et al. Randomized clinical trial of a postdischarge pharmaceutical care program vs . regular follow-up in patients with heart failure. 30;328-42, 2006.
57. Bristow MR, Minobe W, Rasmussen R, Larrabee P, Skerl L, Klein JW, et al. β - Adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. *J Clin Invest*. 89(3);803- 15, 1992.
58. Metra M, Nodari S, Aloia AD, Muneretto C, Robertson AD, Bristow MR, et al. Beta-Blocker Therapy Influences the Hemodynamic Response to Inotropic Agents in Patients With Heart Failure. 40(7), 2002.
59. Study R, Connell JBO, Renlund DG, Bartholomew M, Patrice C, Bristow MR, et al. Long-Term ,& Blocker Vasodilator Therapy Improves Cardiac Function in Idiopathic Dilated Cardiomyopathy : Placebo. 88;223-9, 1990.
60. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. *N Engl J Med*. 334(21):1349-55, 1996.
61. Waagsteinu F. Evidence-based Cardiology Beta-blocking agents in heart failure Should they be used and how ? 1629-39, 2018.

62. Australia/New Zealand Heart Failure Research Collaborative Group A. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. *Lancet*. 349(9049);375–80, 1997.
63. Cheng JWM, Cooke-Ariel H. Pharmacists' role in the care of patients with heart failure: Review and future evolution. *J Manag Care Pharm*. 20(2);206–13, 2014.
64. Davis EM, Packard KA, Jackevicius CA. The Pharmacist Role in Predicting and Improving Medication Adherence in Heart Failure Patients. *J Manag Care Pharm*. 20(7);741–55, 2014.
65. Lain M, Cleland JGF, Lenzen MJ, Nabb S, Keber I, Follath F, et al. Recall of lifestyle advice in patients recently hospitalised with heart failure : A EuroHeart Failure Survey analysis. 9;1095–103, 2007.
66. Wal MHL Van Der, Jaarsma T, Veldhuisen DJ Van. Non-compliance in patients with heart failure ; how can we manage it ? 7;5–17, 2005.
67. Kongkaew C, Noyce PR, Ashcroft DM. Hospital Admissions Associated with Adverse Drug Reactions : A Systematic Review of Prospective Observational Studies OBJECTIVE. 42;1017–25, 2008.
68. Kane SL, Weber RJ, Dasta JF. The impact of critical care pharmacists on enhancing patient outcomes. 691–8; 2003.
69. Akbiyik A, Gör A, Koçak G, Hem U, Oksel E, Doç Y. Kronik Kalp Yetmezliği Olan Hastalarda Öz-Bakim Davranışlarının İncelenmesi Self-Care Behaviours Analysis of Patients with Chronic Heart Failure.1(2);1–8, 2016.
70. Austin S, Mha B, Rn BJW, Mha TLG, Wakefield DS. Heart failure self- management education : a systematic. 159–68, 2009.
71. Sezgin D, Mert H. Kalp Yetersizliği Olan Bireylerin Hemşirelik Bakimında Kanıta Dayalı Yaklaşımlar. 8(2);108–18, 2015.
72. Pk A, Adepu R. Drug related problems: an over view of various classification systems. *Asian J Pharm Clin Res*. 7(4);7–10, 2014.
73. PCNE. Classification for Drug related problems. *PCNE Classif*. 2017.
74. Gastelurrutia P, Benrimoj SI, Espejo J, Tuneu L, Mangues MA, Bayes-Genis A. Negative clinical outcomes associated with drug-related problems in heart failure (HF) outpatients: Impact of a pharmacist in a multidisciplinary HF clinic. *J Card Fail*. 17(3);217–23, 2011.

75. Dahal PR, Venkataraman R FP. Assessment of clinical pharmacist intervention in tertiary care teaching hospital of southern India. *Asian J Pharm Clin Res.* 6(2);258-61, 2013.
76. Eichenberger PM, Lampert ML, Kahmann IV, Van Mil JWF, Hersberger KE. Classification of drug-related problems with new prescriptions using a modified PCNE classification system. *Pharm World Sci.* 32(3);362-72, 2010.
77. PR N, Marusic S, DP de LJ, Pilger D, JM C-S, WP G, et al. Effect of a 36- month pharmaceutical care program on the coronary heart disease risk in elderly diabetic and hypertensive patients. *J Pharm Pharm Sci.* 14(2);249-63, 2011.
78. Catania N. Risk factors for drug-related problems in elderly ambulatory patients Medication use among elderly patients in ambulatory. *Home Care Provid.* 3(1);20-2, 1998.
79. Krähenbühl-Melcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Krähenbühl S. Drug-Related Problems in Hospitals. *Drug Saf.* 30(5);379-407, 2007.
80. Kripalame S. Yao X HB. Interventions to enhance medication adherence in chronic medical conditions. *Arch Intern Med.* 167;540-50, 2007.
81. Blix HS, Viktil KK, Reikvam Å, Moger TA, Hjemaas BJ, Pretsch P, et al. The majority of hospitalised patients have drug-related problems: Results from a prospective study in general hospitals. *Eur J Clin Pharmacol.* 60(9);651-8, 2004.
82. Shareef J, Sandeep B, Shastry CS. Assessment of Drug Related Problems in Patients with Cardiovascular Diseases in a Tertiary Care Teaching Hospital. 2014.
83. Winterstein AG, Sauer BC, Hepler CD, Poole C. Preventable Drug-Related Hospital Admissions Methods : conclusions : data extraction. 36, 2002.
84. Er- PM. Effect of a Pharmacist on Adverse Drug Events and Medication Errors in Outpatients With Cardiovascular Disease. 169(8);757-63, 2009.
85. Anderson C, Blenkinsopp A, Armstrong M. The contribution of community pharmacy to improving the public's health. 2001.
86. Yuksel N, Majumdar SR, Biggs C, Tsuyuki RT. Community pharmacist-initiated screening program for osteoporosis: Randomized controlled trial. *Osteoporos Int.* 21(3);391-8, 2010.
87. Lalonde L, Quintana-Bárcena P, Lord A, Bell R, Clément V, Daigneault AM, et al. Community Pharmacist Training-and-Commu-

- nication Network and Drug- Related Problems in Patients With CKD: A Multicenter, Cluster-Randomized, Controlled Trial. *Am J Kidney Dis.* 70(3);386–96, 2017.
88. Guignard B, Bonnabry P, Perrier A, Dayer P, Desmeules J, Samer CF. Drug- related problems identification in general internal medicine: The impact and role of the clinical pharmacist and pharmacologist. *Eur J Intern Med.* 26(6); 399–406, 2015.
 89. European Directorate for the Quality of Medicine & Healthcare. Pharmaceutical care : Policies and Practices for a Safer, More Responsible and Cost-effective Health System. *Pharm World Sci.* 18(6);233–6, 2012.
 90. Anderson SL, Marrs JC. A Review of the Role of the Pharmacist in Heart Failure Transition of Care. *Adv Ther.* 35(3);311–23, 2018.
 91. Pharmacy M. Effect of pharmaceutical care services on outcomes for home care patients with heart failure. 64, 2007.
 92. Pratt RJ, Robinson N, Loveday HP, Pellowe CM, Franks J, Hankins M, et al. Adherence to Antiretroviral Therapy: Appropriate Use of Self-Reporting in Clinical Practice. 4336, 2015.
 93. Redding IC, Staflord J, Geletko S, Melbourne K, Caro JJ. Stages of Change for Adherence with Medication Regimens for Chronic Disease : Development and Validation of a Measure. 22(7), 2000.
 94. L. Sheng, M. Christopher AM. HHS Public Access. *Physiol Behav.* 176(1);100– 106, 2016.
 95. Shalansky SJ, Levy AR, Ignaszewski AP. Self-reported Morisky score for identifying nonadherence with cardiovascular medications. *Ann Pharmacother.* 38(9);1363–8, 2004.
 96. Noureldin M, Pharm D, Plake KS, Ph D, Morrow DG, Ph D, et al. Effect of Health Literacy on Drug Adherence in Patients with Heart Failure. 2012.
 97. Ho PM, Lambert-kerzner A, Carey EP, Fahdi IE, Bryson CL, Melnyk SD, et al. Multifaceted Intervention to Improve Medication Adherence and Secondary Prevention Measures After Acute Coronary Syndrome Hospital Discharge A Randomized Clinical Trial. 80220(2);186–93, 2014.
 98. Lee VW, Choi LM, Wong WJ, Chung HW, Ng CK, Cheng FW. Pharmacist intervention in the prevention of heart failure for high-risk elderly patients in the community. *BMC Cardiovasc Disord [Internet].* 1–8, 2015.
 99. Varma S, McElnay JC, Hughes CM, Passmore AP, Varma M. Pharmaceutical care of patients with congestive heart failure: Interventions and outcomes. *Pharmacotherapy.* 19(7);860–9, 1999.

100. Hopman WM, Harrison MB, Coe H, Friedberg E, Buchanan M, Vandenkerkhof EG. Associations between chronic disease , age and physical and mental health status. 29(2);108–17, 2009.
101. Silavanich V, Nathisuwan S, Phrommintikul A, Permsuwan U. Relationship of medication adherence and quality of life among heart failure patients. *Hear Lung* [Internet]. 48(2);105–10, 2019.
102. Sadik A, Yousif M, McElnay JC. Pharmaceutical care of patients with heart failure. 183–93, 2005.
103. López Castro J, Cid Conde L, Fernández Rodríguez V, Failde Garrido JM, Almazán Ortega R. Análisis de la calidad de vida en pacientes con insuficiencia cardíaca mediante el cuestionario genérico SF-36. *Rev Calid Asist* [Internet]. 28(6);355–60, 2013.
104. Niriayo YL, Kumela K, Kassa TD, Angamo MT. Drug therapy problems and contributing factors in the management of heart failure patients in Jimma University Specialized Hospital, Southwest Ethiopia. *PLoS One*.13(10);1–14, 2018.
105. Roblek T, Deticek A, Leskovic B, Suskovic S, Horvat M, Belic A. Clinical- pharmacist intervention reduces clinically relevant drug – drug interactions in patients with heart failure : A randomized , double-blind , controlled trial. *Int J Cardiol* [Internet]. 203;647–52, 2016.
106. Allen LaPointe NM, Jollis JG. Medication errors in hospitalized cardiovascular patients. *Arch Intern Med*. 163(12);1461–6, 2003.